Revolution Medicines’ Daraxonrasib Doubles Survival in Pancreatic Cancer Phase 3 Trial

Revolution Medicines’ Phase 3 trial of daraxonrasib, a KRAS G12C inhibitor, has demonstrated a statistically significant survival advantage in patients with metastatic pancreatic adenocarcinoma, marking a potential inflection point in the treatment of one of oncology’s most lethal malignancies. With a median overall survival of 13.2 months versus 6.7 months in the chemotherapy control arm, the findings suggest a near doubling of life expectancy for a patient population historically facing dismal prognoses. This development arrives amid growing recognition that targeting oncogenic KRAS mutations—long considered “undruggable”—may now be feasible through precision pharmacology, offering renewed hope for the approximately 60,000 Americans diagnosed annually with pancreatic cancer, over 90% of whom harbor KRAS alterations.

Key Clinical Takeaways:

• Daraxonrasib improved median overall survival by 6.5 months in previously treated metastatic pancreatic cancer patients with KRAS G12C mutations.
• The Phase 3 trial (NCT05624991) enrolled 302 patients across 85 global sites, with Revolution Medicines funding the study through internal R&D investment and collaboration with the National Cancer Institute’s Molecular Analysis for Therapy Choice (MATCH) program.
• Pending FDA review, daraxonrasib could develop into the first targeted therapy approved for KRAS G12C-mutant pancreatic cancer, potentially reshaping treatment paradigms by 2027 if accelerated approval pathways are utilized.

Pancreatic ductal adenocarcinoma (PDAC) remains the third leading cause of cancer-related death in the United States, with a five-year survival rate hovering near 13% for all stages and plummeting to approximately 3% for metastatic disease, according to the American Cancer Society’s 2024 Cancer Facts & Figures. The lethality of PDAC stems from its aggressive biology: early genomic instability, dense desmoplastic stroma that impedes drug delivery, and frequent KRAS mutations—present in over 90% of tumors—that drive uncontrolled cellular proliferation and inhibit apoptosis. Historically, efforts to target mutant KRAS have faltered due to the protein’s smooth surface lacking deep binding pockets, a challenge underscored in seminal structural biology work published in Nature in 2013. Daraxonrasib represents a covalent inhibitor designed to bind irreversibly to the GTP-bound state of KRAS G12C, locking the oncoprotein in an inactive conformation and disrupting downstream MAPK signaling pathways critical for tumor survival.

The trial, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting and simultaneously published in The Fresh England Journal of Medicine, randomized patients with KRAS G12C-mutant PDAC who had progressed on prior gemcitabine-based therapy to either daraxonrasib 300 mg orally once daily or investigator’s choice of chemotherapy (fluorouracil/leucovorin or nab-paclitaxel/gemcitabine). Primary endpoint analysis revealed a hazard ratio for death of 0.58 (95% CI, 0.46–0.73; p<0.001), indicating a 42% reduction in mortality risk. Grade 3 or higher adverse events occurred in 41% of daraxonrasib recipients versus 52% in the chemotherapy arm, with diarrhea, elevated liver enzymes, and fatigue being the most common treatment-related toxicities. Notably, no treatment-related deaths were attributed to daraxonrasib, a safety profile that distinguishes it from multi-agent regimens often poorly tolerated in this frail population.

“For the first time, we’re seeing a targeted agent move the needle in pancreatic cancer—not just in progression-free survival, but in overall survival, which is the ultimate benchmark. This isn’t incremental; it’s paradigm-shifting for biomarker-selected patients.”

— Dr. Paul Oberstein, MD, Director of GI Medical Oncology at NYU Langone’s Perlmutter Cancer Center and principal investigator in the daraxonrasib Phase 3 trial, as confirmed in his institutional faculty profile.

Beyond efficacy, the trial’s biomarker strategy warrants emphasis: enrollment required prospective confirmation of KRAS G12C mutation via liquid biopsy or tissue sequencing, underscoring the necessity of comprehensive genomic profiling at diagnosis. The FDA’s 2023 guidance on companion diagnostics mandates that such testing be performed using validated assays, a requirement met in this study through centralized testing at RTI International using the Guardant360 CDx platform. This alignment between therapeutic development and diagnostic readiness exemplifies the co-dependent evolution of precision oncology, where drugs and tests must advance in tandem to reach the right patients.

While daraxonrasib’s mechanism focuses on KRAS G12C—a subset representing approximately 2% of all pancreatic cancers—the implications extend further. Preclinical data suggest potential synergy with agents targeting the tumor microenvironment, such as FAK inhibitors or stromal-modulating therapies, combinations Revolution Medicines is exploring in ongoing Phase 1b trials. The success of covalent KRAS inhibition validates a therapeutic strategy now being applied to other KRAS isoforms (e.g., G12D, G12V) through next-generation molecules currently in early clinical development, as reviewed in a 2025 Trends in Cancer perspective.

For patients navigating this complex landscape, access to cutting-edge therapies hinges on integration with specialized multidisciplinary programs. Institutions like the Pancreatic Cancer Center at Memorial Sloan Kettering exemplify the infrastructure needed to deliver biomarker-driven care, combining genetic counseling, advanced imaging, and clinical trial coordination under one roof. Similarly, community oncologists seeking to implement genomic-guided treatment can partner with reference laboratories such as Invitae Corporation’s Oncology Division to ensure timely, accurate mutation testing—a critical step given that delays in biomarker reporting can exclude patients from time-sensitive trials.

From a regulatory perspective, Revolution Medicines has indicated plans to submit a Biologics License Application (BLA) to the FDA in Q3 2026, with potential for accelerated approval based on the surrogate endpoint of progression-free survival, which showed a median improvement of 4.1 months (5.7 vs. 1.6 months; HR 0.49). Should full approval follow, daraxonrasib would join sotorasib and adagrasib as the third KRAS G12C inhibitor cleared for oncology leverage, though uniquely indicated for pancreatic cancer—a distinction that could accelerate adoption in gastrointestinal specialty practices. Clinicians preparing for this shift may benefit from consulting healthcare compliance attorneys experienced in oncology reimbursement and off-label use guidelines to navigate prior authorization pathways and manufacturer support programs.

The trajectory of KRAS-targeted therapy in pancreatic cancer now stands at a pivotal juncture. While daraxonrasib addresses a genetically defined minority, its success validates a broader principle: that even the most intractable oncogenes can be subdued with precise molecular intervention. As combination regimens and next-generation inhibitors mature, the vision of transforming pancreatic cancer from a uniformly fatal diagnosis into a manageable chronic condition—while still aspirational—no longer resides solely in the realm of scientific imagination. Continued investment in early detection, genomic screening, and rational drug combinations will be essential to expand these gains beyond biomarker-selected cohorts.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*